Epidemiologic studies have correlated elevated plasma fibrinogen (hyperfibrinogenemia) with risk of cardiovascular disease and arterial and venous thrombosis. However, it is unknown whether hyperfibrinogenemia is merely a biomarker of the proinflammatory disease state or is a causative mechanism in the etiology. We raised plasma fibrinogen levels in mice via intravenous infusion and induced thrombosis by ferric chloride application to the carotid artery (high shear) or saphenous vein (lower shear); hyperfibrinogenemia significantly shortened the time to occlusion in both models. Using immunohistochemistry, turbidity, confocal microscopy, and elastometry of clots produced in cell and tissue factor-initiated models of thrombosis, we show that hyperfibrinogenemia increased thrombus fibrin content, promoted faster fibrin formation, and increased fibrin network density, strength, and stability. Hyperfibrinogenemia also increased thrombus resistance to tenecteplase-induced thrombolysis in vivo. These data indicate that hyperfibrinogenemia directly promotes thrombosis and thrombolysis resistance and does so via enhanced fibrin formation and stability. These findings strongly suggest a causative role for hyperfibrinogenemia in acute thrombosis and have significant implications for thrombolytic therapy. Plasma fibrinogen levels may be used to identify patients at risk for thrombosis and inform thrombolytic administration for treating acute thrombosis/thromboembolism.
IntroductionElevated plasma fibrinogen is associated with risk of cardiovascular disease and arterial and venous thrombosis. [1][2][3][4][5][6][7][8][9] Several studies have detected dose effects, with increased risk of death or thrombosis in subjects with the highest plasma fibrinogen concentrations. [6][7][8][9] The Framingham 7 and Fragmin During Instability in Coronary Artery Disease 8 studies positively correlated fibrinogen levels with risk of cardiovascular disease and incidence of death and/or myocardial infarction, respectively. The Leiden Thrombophilia Study showed that persons with elevated fibrinogen levels (4.0-4.9 vs Ͻ 3.0 mg/mL, 130%-160% of normal) have an adjusted odds ratio for venous thrombosis of 1.6, whereas persons with Ն 5 mg/mL fibrinogen (Ն 170% of normal) have a 4-fold higher thrombotic risk, even after adjusting for C-reactive protein levels. 9 These epidemiologic studies suggest that elevated fibrinogen is an independent risk factor for both arterial and venous thrombosis and therefore a potential diagnostic and therapeutic target for predicting and reducing thrombosis.Importantly, however, epidemiologic studies have not and cannot show a causal relationship between fibrinogen and disease etiology. 2,10,11 Fibrinogen levels increase with age, inflammatory processes, hematocrit, hypertension, glucose intolerance, cigarette smoking, and adiposity, and high fibrinogen levels increase plasma viscosity, a demonstrated risk factor for coronary heart disease. 5,6,12 These potential confounders have not permitted distinction between fibr...